Original title: Novartis and 1 Drug Network (YI.US) will actively cooperate to explore new models of psoriatic disease management Source: Zhitong Financial Network

Zhitong Financial Network

On September 24, 2020, the 3rd China Internet Medicine and Health Summit hosted by 1 Pharmaceutical Network (YI.US) was held in Shanghai. The theme of the summit was “Digital Links · Technology Inclusion”, bringing together many professional elites in the medical and health field, such as pharmaceutical company executives and big investors. During the summit, Novartis Pharmaceuticals (China) (hereinafter referred to as “Novartis”) and 1 Pharmaceutical Network jointly announced the “Yinju Future - Psoriatic Disease Management” project, which will actively explore new models of cooperation in the field of “Internet+Psoriatic Disease”. The project ceremony was attended by guests including Ms. Zhang Ying, CEO of Novartis Pharmaceuticals (China), and Dr. Yu Gang, co-founder and executive chairman of 1 Pharmaceutical Network.

1 Drug Network will provide a one-stop “medical+medicine” service for patients with psoriasis. At the same time, the two sides will explore the use of Novartis's expertise in innovative medicine for psoriasis to better serve patients. Furthermore, by laying out a nationwide intelligent supply chain system through the 1 drug network, the accessibility of innovative drugs for psoriasis will be greatly improved, and patients will be able to receive door-to-door drug delivery and personalized services at home.

This time, 1 Drug Network also plans to invite Novartis to work with it to actively explore new models of disease management in the field of Internet+ psoriasis, use the power of digital technologies such as Internet technology, big data, cloud service solutions, and intelligent supply chains to further optimize patients' disease management processes, further improve patients' medication compliance through systematic CRM management, enhance the medication experience and self-management awareness of psoriasis patients, so that more patients with psoriasis can correctly understand the disease.

Under the current imbalance between supply and demand for medical resources, the cooperation projects being explored by the two sides will help achieve dynamic links between patients and doctors outside the hospital, help solve the convenience of diagnosis and treatment of patients with psoriasis, reduce the burden of work on doctors, improve work efficiency, and facilitate the efficient and rational use of medical resources.

Ms. Zhang Ying, CEO of Novartis Pharmaceuticals (China), said that the epidemic has further accelerated the development of the Internet healthcare industry. The Internet can not only improve the accessibility of medicines, but also provide great convenience for patients to obtain medical services. Novartis has deep expertise in innovative drug development and disease research, and has established strong advantages in various areas such as online medical services, big data, and intelligent supply chains.

Listed by the World Health Organization as one of the top ten persistent diseases of the 21st century, psoriasis is a chronic, recurrent, inflammatory, systemic disease mediated by immunity. Psoriatic disease has a long course and is prone to recurrence. Some cases are almost never cured for the rest of their lives. Currently, there are about 125 million people with psoriasis worldwide and 6.5 million in China. Since patients lack scientific awareness of disease management, how to help patients manage the entire course of the disease and how to achieve long-term follow-up of patients is becoming a problem that the industry urgently needs to solve.

Dr. Yu Gang, co-founder and executive chairman of 1 Drug Network, said that difficulties in seeing a doctor and buying medicine have always been pain points for Chinese patients. The mission of 1 Drug Network is to use digital technology to organically connect patients with drugs and medical services. This collaborative exploration with Novartis in the field of “Internet+Psoriasis” can not only meet the needs of patients, but also meet the future development trend of the industry. We expect the two sides to make full use of their resources and advantages in their respective fields, continue to explore more efficient models of psoriasis disease management, care for the health and lives of more patients, benefit more patients, and help build a “healthy China 2030.”